Sex differences in stroke: The contribution of coagulation

Experimental Neurology

Volumn 259, Issue , 2014, Pages 16-27

  Roy O'Reilly, Meaghan ^a   McCullough, Louise D ^a,b  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

Cerebral ischemia; Estrogen; Thrombosis; Vasculature; Women

Indexed keywords

ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; ESTROGEN; ORAL CONTRACEPTIVE AGENT; PLASMINOGEN; TESTOSTERONE; TISSUE PLASMINOGEN ACTIVATOR; BLOOD CLOTTING FACTOR;

ANTICOAGULANT THERAPY; BLOOD CLOT LYSIS; BLOOD CLOTTING; BLOOD VESSEL REACTIVITY; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DISABILITY; DISEASE COURSE; DRUG EFFICACY; ENDOTHELIUM CELL; FIBRINOLYSIS; GENETIC MODEL; HIGH RISK POPULATION; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HYPERCOAGULABILITY; MENOPAUSE; METABOLIC SYNDROME X; NONHUMAN; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PLATELET REACTIVITY; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX CHROMOSOME; SEX DIFFERENCE; THROMBOSIS; UNITED STATES; VEIN THROMBOSIS; BRAIN CIRCULATION; FEMALE; FIBRINOLYTIC THERAPY; GENETICS; HUMAN CHROMOSOME; MALE; PHYSIOLOGY; SEXUAL DEVELOPMENT; THROMBOCYTE; VASCULARIZATION;

CEREBRAL ISCHEMIA; ESTROGEN; THROMBOSIS; VASCULATURE; WOMEN;

BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD PLATELETS; CEREBROVASCULAR CIRCULATION; CHROMOSOMES, HUMAN; FEMALE; HUMANS; MALE; SEX CHARACTERISTICS; STROKE; THROMBOLYTIC THERAPY;

EID: 84907291499     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2014.02.011     Document Type: Review

References (178)

1. Adams, H.P. Jr., Bendixen, B.H., Kappelle, L.J., et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:1 (1993), 35–41 (Jan).
2. Ahmed, S.A., Verthelyi, D., Antibodies to cardiolipin in normal C57BL/6J mice: induction by estrogen but not dihydrotestosterone. J. Autoimmun. 6:3 (1993), 265–279 (Jun).
3. 2 reactivity and chemoreflex control of breathing: mechanisms of regulation, measurement, and interpretation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296:5 (2009), R1473–R1495 (May).
4. Anand, S.S., Yi, Q., Gerstein, H., et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 108:4 (2003), 420–425.
5. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Neurology 43:10 (1993), 2069–2073 (Oct).
6. Collaborative overview of randomised trials of antiplatelet therapy—I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 308:6921 (1994), 81–106 (Jan 8).
7. Arenillas, J.F., Moro, M.A., Dávalos, A., The metabolic syndrome and stroke: potential treatment approaches. Stroke 38:7 (2007), 2196–2203.
8. Arenillas, J.F., Ispierto, L., Millan, M., et al. Metabolic syndrome and resistance to IV thrombolysis in middle cerebral artery ischemic stroke. Neurology 71:3 (2008), 190–195.
9. Arenillas, J.F., Sandoval, P., Pérez de la Ossa, N., et al. The metabolic syndrome is associated with a higher resistance to intravenous thrombolysis for acute ischemic stroke in women than in men. Stroke 40:2 (2009), 344–349.
10. Arnold, A.P., The organizational–activational hypothesis as the foundation for a unified theory of sexual differentiation of all mammalian tissues. Horm. Behav. 55:5 (2009), 570–578 (May).
11. Arnold, A.P., Mouse models for evaluating sex chromosome effects that cause sex differences in non-gonadal tissues. J. Neuroendocrinol. 21:4 (2009), 377–386 (Mar).
12. Arnold, A.P., Chen, X., What does the “four core genotypes” mouse model tell us about sex differences in the brain and other tissues?. Front. Neuroendocrinol. 30:1 (2009), 1–9 (Jan).
13. Ayala, C., Croft, J.B., Greenlund, K.J., et al. Sex differences in US mortality rates for stroke and stroke subtypes by race/ethnicity and age, 1995–1998. Stroke 33:5 (2002), 1197–1201 (May).
14. Baillargeon, J.P., McClish, D.K., Essah, P.A., Nestler, J.E., Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J. Clin. Endocrinol. Metab. 90:7 (2005), 3863–3870.
15. Bar, J., Lahav, J., Hod, M., Ben-Rafael, Z., Weinberger, I., Brosens, J., Regulation of platelet aggregation and adenosine triphosphate release in vitro by 17beta-estradiol and medroxyprogesterone acetate in postmenopausal women. Thromb. Haemost. 84:4 (2000), 695–700 (Oct).
16. Baron, J.C., Perfusion thresholds in human cerebral ischemia: historical perspective and therapeutic implications. Cerebrovasc. Dis. 11:Suppl. 1 (2001), 2–8.
17. Bath, P.M., Gray, L.J., Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ, 330(7487), 2005, 342 (Feb 12).
18. Becker, D.M., Segal, J., Vaidya, D., et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 295:12 (2006), 1420–1427.
19. Bellamy, L., Casas, J.P., Hingorani, A.D., Williams, D.J., Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ, 335(7627), 2007, 974.
20. Berger, J.S., Roncaglioni, M.C., Avanzini, F., Pangrazzi, I., Tognoni, G., Brown, D.L., Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 295:3 (2006), 306–313.
21. Berger, J.S., Bhatt, D.L., Cannon, C.P., et al. The relative efficacy and safety of clopidogrel in women and men: a sex-specific collaborative meta-analysis. J. Am. Coll. Cardiol. 54:21 (2009), 1935–1945 (11/17).
22. Billeci, A.M., Paciaroni, M., Caso, V., Agnelli, G., Hormone replacement therapy and stroke. Curr. Vasc. Pharmacol. 6:2 (2008), 112–123 (Apr).
23. Boden-Albala, B., Sacco, R.L., Lee, H.S., et al. Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study. Stroke 39:1 (2008), 30–35 (Jan).
24. Brass, L.M., Hormone replacement therapy and stroke: clinical trials review. Stroke 35:11 Suppl. 1 (2004), 2644–2647.
25. Bremme, K.A., Haemostatic changes in pregnancy. Best Pract. Res. Clin. Haematol. 16:2 (2003), 153–168 (Jun).
26. Brey, R.L., Abbott, R.D., Curb, J.D., et al. Beta(2)-glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu Heart Program. Stroke 32:8 (2001), 1701–1706 (Aug).
27. Brey, R.L., Stallworth, C.L., McGlasson, D.L., et al. Antiphospholipid antibodies and stroke in young women. Stroke 33:10 (2002), 2396–2400 (Oct).
28. Broderick, J.P., Palesch, Y.Y., Demchuk, A.M., et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N. Engl. J. Med. 368:10 (2013), 893–903 (2013/03/07).
29. Brown, M.C., Best, K.E., Pearce, M.S., Waugh, J., Robson, S.C., Bell, R., Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur. J. Epidemiol. 28:1 (2013), 1–19.
30. Buck, B., Kim, D., Sayer, J., et al. The volume of middle cerebral artery thrombi: assessment by GRE MRI, gender differences, and relation to response to fibrinolytic therapy. Stroke, 37(2), 2006, 648.
31. Bugge, T.H., Xiao, Q., Kombrinck, K.W., et al. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc. Natl. Acad. Sci. U. S. A. 93:13 (1996), 6258–6263.
32. Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL, Howard VJ, Lichtman JH, Lisabeth LD, Piña IL, Reeves MJ, Rexrode KM, Saposnik G, Singh V, Towfighi A, Vaccarino V, Walters MR; on behalf of the American Heart Association Stroke Council, 2014. Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Council for High Blood Pressure Research. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. [published online ahead of print February 6, 2014]. Stroke. http://dx.doi.org/10.1161/01.str.0000442009.06663.48.
33. Canonico, M., Oger, E., Plu-Bureau, G., et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 115:7 (2007), 840–845.
34. Chakhtoura, Z., Canonico, M., Gompel, A., Thalabard, J.C., Scarabin, P.Y., Plu-Bureau, G., Progestogen-only contraceptives and the risk of stroke: a meta-analysis. Stroke 40:4 (2009), 1059–1062 (Apr).
35. Chan, W.S., Ray, J., Wai, E.K., et al. Risk of stroke in women exposed to low-dose oral contraceptives: a critical evaluation of the evidence. Arch. Intern. Med. 164:7 (2004), 741–747.
36. Ciccone, A., Valvassori, L., Nichelatti, M., et al. Endovascular treatment for acute ischemic stroke. N. Engl. J. Med. 368:10 (2013), 904–913 (2013/03/07).
37. Cleuren, A.C., Van der Linden, I.K., De Visser, Y.P., Wagenaar, G.T., Reitsma, P.H., Van Vlijmen, B.J., 17Alpha-ethinylestradiol rapidly alters transcript levels of murine coagulation genes via estrogen receptor alpha. J. Thromb. Haemost. 8:8 (2010), 1838–1846 (Aug).
38. Dan, P., Cheung, J.C., Scriven, D.R., Moore, E.D., Epitope-dependent localization of estrogen receptor-alpha, but not -beta, in en face arterial endothelium. Am. J. Physiol. Heart Circ. Physiol. 284:4 (2003), H1295–H1306 (Apr).
39. Davis, E.F., Newton, L., Lewandowski, A.J., et al. Pre-eclampsia and offspring cardiovascular health: mechanistic insights from experimental studies. Clin. Sci. (Lond.) 123:2 (2012), 53–72 (Jul).
40. Davis, C.M., Fairbanks, S.L., Alkayed, N.J., Mechanism of the sex difference in endothelial dysfunction after stroke. Transl. Stroke Res. 4:4 (2013), 381–389.
41. del Rio-Espinola, A., Fernandez-Cadenas, I., Giralt, D., et al. A predictive clinical–genetic model of tissue plasminogen activator response in acute ischemic stroke. Ann. Neurol. 72:5 (2012), 716–729 (Nov).
42. Douketis, J., Tosetto, A., Marcucci, M., et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ, 342, 2011, d813.
43. DS, L., Laughton, A., Kim, D., et al. Vessel size explains gender differences in response to intravenous thrombolysis for acute stroke. Stroke, 37(2), 2006, 622.
44. Duckles, S.P., Krause, D.N., Mechanisms of cerebrovascular protection: oestrogen, inflammation and mitochondria. Acta Physiol (Oxf.) 203:1 (2011), 149–154 (Sep).
45. Duckles, S.P., Krause, D.N., Stirone, C., Procaccio, V., Estrogen and mitochondria: a new paradigm for vascular protection?. Mol. Interv. 6:1 (2006), 26–35 (Feb).
46. Eliasson, M., Evrin, P.E., Lundblad, D., Asplund, K., Rånby, M., Influence of gender, age and sampling time on plasma fibrinolytic variables and fibrinogen: a population study. Fibrinolysis 7:5 (1993), 316–323 (9).
47. Emms, H., Lewis, G.P., The effect of synthetic ovarian hormones on an in vivo model of thrombosis in the rat. Br. J. Pharmacol. 84:1 (1985), 243–248 (Jan).
48. Emms, H., Lewis, G.P., Sex and hormonal influences on platelet sensitivity and coagulation in the rat. Br. J. Pharmacol. 86:3 (1985), 557–563 (Nov).
49. Farsetti, A., Misiti, S., Citarella, F., et al. Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology 136:11 (1995), 5076–5083 (Nov).
50. Finazzi, G., Marchioli, R., Brancaccio, V., et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J. Thromb. Haemost. 3:5 (2005), 848–853 (May).
51. Folbergrova, J., Memezawa, H., Smith, M.L., Siesjo, B.K., Focal and perifocal changes in tissue energy state during middle cerebral artery occlusion in normo- and hyperglycemic rats. J. Cereb. Blood Flow Metab. 12:1 (1992), 25–33 (Jan).
52. Folsom, A.R., Aleksic, N., Catellier, D., Juneja, H.S., Wu, K.K., C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. Am. Heart J. 144:2 (2002), 233–238 (Aug).
53. Faraday, N., Goldschmidt-Clermont, P.J., Bray, P.F., Gender differences in platelet GPIIb-IIIa activation. Thromb. Haemost. 77:4 (1997), 748–754.
54. Gailani, D., Renne, T., The intrinsic pathway of coagulation: a target for treating thromboembolic disease?. J. Thromb. Haemost. 5:6 (2007), 1106–1112 (Jun).
55. Gall, S.L., Tran, P.L., Martin, K., Blizzard, L., Srikanth, V., Sex differences in long-term outcomes after stroke: functional outcomes, handicap, and quality of life. Stroke 43:7 (2012), 1982–1987.
56. Gargano, J.W., Wehner, S., Reeves, M., Sex differences in acute stroke care in a statewide stroke registry. Stroke 39:1 (2008), 24–29 (Jan).
57. Geary, G.G., Krause, D.N., Duckles, S.P., Estrogen reduces mouse cerebral artery tone through endothelial NOS- and cyclooxygenase-dependent mechanisms. Am. J. Physiol. Heart Circ. Physiol. 279:2 (2000), H511–H519 (Aug).
58. Geary, G.G., McNeill, A.M., Ospina, J.A., Krause, D.N., Korach, K.S., Duckles, S.P., Selected contribution: cerebrovascular NOS and cyclooxygenase are unaffected by estrogen in mice lacking estrogen receptor-α. J. Appl. Physiol. 91:5 (2001), 2391–2399.
59. Gebara, O.C., Mittleman, M.A., Sutherland, P., et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 91:7 (1995), 1952–1958.
60. Gillum, L.A., Mamidipudi, S.K., Johnston, S.C., Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA 284:1 (2000), 72–78.
61. Glass, C.K., Witztum, J.L., Atherosclerosis. The road ahead. Cell 104:4 (2001), 503–516 (Feb 23).
62. Go, A.S.M., Mozaffarian, D.M., DrPH, F.A.H.A., Roger, V.L.M., MPH, F.A.H.A., et al. Executive summary: heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation 127:1 (2013), 143–152.
63. Goldstein, L.B., Adams, R., Alberts, M.J., et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Stroke 37:6 (2006), 1583–1633.
64. Gonzales, R.J., Androgens and the cerebrovasculature: modulation of vascular function during normal and pathophysiological conditions. Pflugers Arch. 465:5 (2013), 627–642 (May).
65. Gonzales, R.J., Ghaffari, A.A., Duckles, S.P., Krause, D.N., Testosterone treatment increases thromboxane function in rat cerebral arteries. Am. J. Physiol. Heart Circ. Physiol. 289:2 (2005), H578–H585.
66. Goto, T., Monk, M., Regulation of X-chromosome inactivation in development in mice and humans. Microbiol. Mol. Biol. Rev. 62:2 (1998), 362–378 (Jun).
67. Govers-Riemslag, J.W., Smid, M., Cooper, J.A., et al. The plasma kallikrein–kinin system and risk of cardiovascular disease in men. J. Thromb. Haemost. 5:9 (2007), 1896–1903 (Sep).
68. Grundy, S.M., Cleeman, J.I., Daniels, S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:17 (2005), 2735–2752.
69. Guo, J., Krause, D.N., Horne, J., Weiss, J.H., Li, X., Duckles, S.P., Estrogen-receptor-mediated protection of cerebral endothelial cell viability and mitochondrial function after ischemic insult in vitro. J. Cereb. Blood Flow Metab. 30:3 (2010), 545–554 (Mar).
70. Gupta, A., Chazen, J.L., Hartman, M., et al. Cerebrovascular reserve and stroke risk in patients with carotid stenosis or occlusion: a systematic review and meta-analysis. Stroke 43:11 (2012), 2884–2891 (Nov).
71. Gupta, N.C., Davis, C.M., Nelson, J.W., Young, J.M., Alkayed, N.J., Soluble epoxide hydrolase: sex differences and role in endothelial cell survival. Arterioscler. Thromb. Vasc. Biol. 32:8 (2012), 1936–1942 (Aug).
72. Haast, R.A.M., Gustafson, D.R., Kiliaan, A.J., Sex differences in stroke. J. Cereb. Blood Flow Metab. 32:12 (2012), 2100–2107 (12//print).
73. Hagberg, H., Wilson, M.A., Matsushita, H., et al. PARP-1 gene disruption in mice preferentially protects males from perinatal brain injury. J. Neurochem. 90:5 (2004), 1068–1075 (Sep).
74. Hagedorn, I., Schmidbauer, S., Pleines, I., et al. Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation 121:13 (2010), 1510–1517.
75. 2 +-calmodulin dependent mechanism. Biochem. Biophys. Res. 203:2 (1994), 1013–1019 (9/15/).
76. Heard, E., Disteche, C.M., Dosage compensation in mammals: fine-tuning the expression of the X chromosome. Genes Dev. 20:14 (2006), 1848–1867.
77. Heinzlef, O., Abuaf, N., Cohen, A., Amarenco, P., Recurrent stroke and vascular events in elderly patients with anticardiolipin antibodies: a prospective study. J. Neurol. 248:5 (2001), 373–379 (May).
78. Heiss, G., Wallace, R., Anderson, G.L., et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 299:9 (2008), 1036–1045.
79. Hill, M.D., Kent, D.M., Hinchey, J., et al. Sex-based differences in the effect of intra-arterial treatment of stroke: analysis of the PROACT-2 study. Stroke 37:9 (2006), 2322–2325 (Sep).
80. Holmegard, H.N., Nordestgaard, B.G., Schnohr, P., Tybjaerg-Hansen, A., Benn, M., Endogenous sex hormones and risk of venous thromboembolism in women and men. J. Thromb. Haemost., 2013 (Electronic publication ahead of print, Dec 11).
81. Howard, B.V., Rossouw, J.E., Estrogens and cardiovascular disease risk revisited: the Women's Health Initiative. Curr. Opin. Lipidol. 24:6 (2013), 493–499 (Dec).
82. Hunt, B.J., Khamashta, M.A., Antiphospholipid antibodies and the endothelium. Curr. Rheumatol. Rep. 2:3 (2000), 252–255 (Jun).
83. Iliff, J.J., Jia, J., Nelson, J., Goyagi, T., Klaus, J., Alkayed, N.J., Epoxyeicosanoid signaling in CNS function and disease. Prostaglandins Other Lipid Mediat. 91:3–4 (2010), 68–84 (Apr).
84. James, A.H., Bushnell, C.D., Jamison, M.G., Myers, E.R., Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet. Gynecol. 106:3 (2005), 509–516 (Sep).
85. Janardhan, V., Wolf, P.A., Kase, C.S., et al. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study. Stroke 35:3 (2004), 736–741 (Mar).
86. Jayachandran, M., Miller, V.M., Human platelets contain estrogen receptor alpha, caveolin-1 and estrogen receptor associated proteins. Platelets 14:2 (2003), 75–81 (Mar).
87. Jayachandran, M., Owen, W.G., Miller, V.M., Effects of ovariectomy on aggregation, secretion, and metalloproteinases in porcine platelets. Am. J. Physiol. Heart Circ. Physiol. 284:5 (2003), H1679–H1685.
88. Johnson, M., Ramey, E., Ramwell, P.W., Androgen-mediated sensitivity in platelet aggregation. Am. J. Physiol. 232:4 (1977), H381–H385 (Apr).
89. Kain, K., Carter, A.M., Bamford, J.M., Grant, P.J., Catto, A.J., Gender differences in coagulation and fibrinolysis in white subjects with acute ischemic stroke. J. Thromb. Haemost. 1 (2003), 390–392 (England).
90. Kauser, K., Rubanyi, G.M., Gender difference in bioassayable endothelium-derived nitric oxide from isolated rat aortae. Am. J. Physiol. 267:6 Pt 2 (1994), H2311–H2317 (Dec).
91. Kauser, K., Rubanyi, G.M., Gender difference in endothelial dysfunction in the aorta of spontaneously hypertensive rats. Hypertension 25:4 (1995), 517–523.
92. Kemmeren, J.M., Tanis, B.C., van den Bosch, M.A., et al. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke 33:5 (2002), 1202–1208 (May).
93. Kent, D.M., Price, L.L., Ringleb, P., Hill, M.D., Selker, H.P., Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke: a pooled analysis of randomized clinical trials. Stroke 36:1 (2005), 62–65 (Jan).
94. Kent, D.M., Buchan, A.M., Hill, M.D., The gender effect in stroke thrombolysis: of CASES, controls, and treatment-effect modification. Neurology 71:14 (2008), 1080–1083.
95. Khamashta, M.A., Cuadrado, M.J., Mujic, F., Taub, N.A., Hunt, B.J., Hughes, G.R.V., The management of thrombosis in the antiphospholipid-antibody syndrome. N. Engl. J. Med. 332:15 (1995), 993–997 (1995/04/13).
96. Kidwell, C.S., Jahan, R., Gornbein, J., et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N. Engl. J. Med. 368:10 (2013), 914–923 (2013/03/07).
97. Kim, K.H., Bender, J.R., Membrane-initiated actions of estrogen on the endothelium. Mol. Cell. Endocrinol. 308:1–2 (2009), 3–8.
98. King, A., Serena, J., Bornstein, N.M., Markus, H.S., Does impaired cerebrovascular reactivity predict stroke risk in asymptomatic carotid stenosis? A prospective substudy of the asymptomatic carotid emboli study. Stroke 42:6 (2011), 1550–1555 (Jun).
99. Kleinschnitz, C., Stoll, G., Bendszus, M., et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J. Exp. Med. 203:3 (2006), 513–518.
100. Krause, D.N., Duckles, S.P., Pelligrino, D.A., Influence of sex steroid hormones on cerebrovascular function. J. Appl. Physiol. 101:4 (2006), 1252–1261.
101. Kurrelmeyer, K., Becker, L., Becker, D., Yanek, L., Goldschmidt-Clermont, P., Bray, P.F., Platelet hyperreactivity in women from families with premature atherosclerosis. J. Am. Med. Womens Assoc. 58:4 (2003), 272–277.
102. LaCroix, A.Z., Chlebowski, R.T., Manson, J.E., et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 305:13 (2011), 1305–1314.
103. Latham, K.E., X chromosome imprinting and inactivation in preimplantation mammalian embryos. Trends Genet. 21:2 (2005), 120–127 (Feb).
104. Leng, X.H., Hong, S.Y., Larrucea, S., et al. Platelets of female mice are intrinsically more sensitive to agonists than are platelets of males. Arterioscler. Thromb. Vasc. Biol. 24:2 (2004), 376–381 (Feb).
105. Levine, S.R., Brey, R.L., Tilley, B.C., et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 291:5 (2004), 576–584.
106. Li, H., Pin, S., Zeng, Z., Wang, M.M., Andreasson, K.A., McCullough, L.D., Sex differences in cell death. Ann. Neurol. 58:2 (2005), 317–321 (Aug).
107. Lidegaard, O., Lokkegaard, E., Jensen, A., Skovlund, C.W., Keiding, N., Thrombotic stroke and myocardial infarction with hormonal contraception. N. Engl. J. Med. 366:24 (2012), 2257–2266.
108. Liu, M., Oyarzabal, E.A., Yang, R., Murphy, S.J., Hurn, P.D., A novel method for assessing sex-specific and genotype-specific response to injury in astrocyte culture. J. Neurosci. Methods 171:2 (2008), 214–217.
109. Liu, F., Yuan, R., Benashski, S.E., McCullough, L.D., Changes in experimental stroke outcome across the life span. J. Cereb. Blood Flow Metab. 29:4 (2009), 792–802 (Apr).
110. Liu, F., Benashski, S.E., Xu, Y., Siegel, M., McCullough, L.D., Effects of chronic and acute oestrogen replacement therapy in aged animals after experimental stroke. J. Neuroendocrinol. 24:2 (2012), 319–330 (Feb).
111. Mackman, N., Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler. Thromb. Vasc. Biol. 24:6 (2004), 1015–1022 (Jun).
112. Malik, S., Wong, N.D., Franklin, S.S., et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110:10 (2004), 1245–1250.
113. Mansfield, M.W., Heywood, D.M., Grant, P.J., Sex differences in coagulation and fibrinolysis in white subjects with non-insulin-dependent diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 16:1 (1996), 160–164 (Jan).
114. Marjoribanks, J., Farquhar, C., Roberts, H., Lethaby, A., Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst. Rev., 7, 2012, Cd004143.
115. McCullough, L.D., Hurn, P.D., Estrogen and ischemic neuroprotection: an integrated view. Trends Endocrinol. Metab. 14:5 (2003), 228–235 (Jul).
116. McCullough, L.D., Zeng, Z., Blizzard, K.K., Debchoudhury, I., Hurn, P.D., Ischemic nitric oxide and poly(ADP-ribose) polymerase-1 in cerebral ischemia: male toxicity, female protection. J. Cereb. Blood Flow Metab. 25:4 (2005), 502–512 (Apr).
117. McDonald, S.D., Malinowski, A., Zhou, Q., Yusuf, S., Devereaux, P.J., Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am. Heart J. 156:5 (2008), 918–930.
118. McNeill, A.M., Kim, N., Duckles, S.P., Krause, D.N., Kontos, H.A., Chronic estrogen treatment increases levels of endothelial nitric oxide synthase protein in rat cerebral microvessels. Stroke 30:10 (1999), 2186–2190 (Oct).
119. McNeill, A.M., Zhang, C., Stanczyk, F.Z., Duckles, S.P., Krause, D.N., Estrogen increases endothelial nitric oxide synthase via estrogen receptors in rat cerebral blood vessels: effect preserved after concurrent treatment with medroxyprogesterone acetate or progesterone. Stroke 33:6 (2002), 1685–1691.
120. Mehta, S.R., Yusuf, S., Peters, R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358:9281 (2001), 527–533.
121. Mendelsohn, M.E., Karas, R.H., The protective effects of estrogen on the cardiovascular system. N. Engl. J. Med. 340:23 (1999), 1801–1811 (1999/06/10).
122. Miller, V.M., Duckles, S.P., Vascular actions of estrogens: functional implications. Pharmacol. Rev. 60:2 (2008), 210–241.
123. Montano, A., Staff, I., McCullough, L.D., Fortunato, G., Community implementation of intravenous thrombolysis for acute ischemic stroke in the 3- to 4.5-hour window. Am. J. Emerg. Med. 31:12 (2013), 1707–1709.
124. Mosher, W.D., Jones, J., Use of contraception in the United States: 1982–2008. Vital Health Stat. 23:29 (2010), 1–44 (Aug).
125. Nguyen-Huynh, M.N., Johnston, S.C., Is mechanical clot removal or disruption a cost-effective treatment for acute stroke?. Am. J. Neuroradiol. 32:2 (2011), 244–249.
126. Niewada, M., Kobayashi, A., Sandercock, P.A., Kaminski, B., Czlonkowska, A., Influence of gender on baseline features and clinical outcomes among 17,370 patients with confirmed ischaemic stroke in the international stroke trial. Neuroepidemiology 24:3 (2005), 123–128.
127. Ospina, J.A., Krause, D.N., Duckles, S.P., 17β-Estradiol increases rat cerebrovascular prostacyclin synthesis by elevating cyclooxygenase-1 and prostacyclin synthase. Stroke 33:2 (2002), 600–605.
128. Ospina, J.A., Duckles, S.P., Krause, D.N., 17β-Estradiol decreases vascular tone in cerebral arteries by shifting COX-dependent vasoconstriction to vasodilation. Am. J. Physiol. Heart Circ. Physiol. 285:1 (2003), H241–H250.
129. Ossei-Gerning, N., Wilson, I.J., Grant, P.J., Sex differences in coagulation and fibrinolysis in subjects with coronary artery disease. Thromb. Haemost. 79:4 (1998), 736–740 (Apr).
130. Ovbiagele, B., Goldstein, L.B., Higashida, R.T., et al. Forecasting the future of stroke in the United States: a policy statement from the American Heart Association and American Stroke Association. Stroke 44 (2013), 2361–2375.
131. Paganini-Hill, A., Hormone replacement therapy and stroke: risk, protection or no effect?. Maturitas 38:3 (2001), 243–261.
132. Paolucci, S., Bragoni, M., Coiro, P., et al. Is sex a prognostic factor in stroke rehabilitation? A matched comparison. Stroke 37:12 (2006), 2989–2994 (Dec).
133. Petrea, R.E., Beiser, A.S., Seshadri, S., Kelly-Hayes, M., Kase, C.S., Wolf, P.A., Gender differences in stroke incidence and poststroke disability in the Framingham Heart Study. Stroke 40:4 (2009), 1032–1037.
134. Prothero, K.E., Stahl, J.M., Carrel, L., Dosage compensation and gene expression on the mammalian X chromosome: one plus one does not always equal two. Chromosome Res. 17:5 (2009), 637–648.
135. Putaala, J., Metso, A.J., Metso, T.M., et al. Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke: the Helsinki Young Stroke Registry. Stroke 40:4 (2009), 1195–1203 (Apr).
136. Renne, T., Pozgajova, M., Gruner, S., et al. Defective thrombus formation in mice lacking coagulation factor XII. J. Exp. Med. 202:2 (2005), 271–281.
137. Renolleau, S., Fau, S., Goyenvalle, C., et al. Specific caspase inhibitor Q-VD-OPh prevents neonatal stroke in P7 rat: a role for gender. J. Neurochem. 100:4 (2007), 1062–1071 (Feb).
138. Ridker, P.M., Rifai, N., Rose, L., Buring, J.E., Cook, N.R., Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347:20 (2002), 1557–1565 (2002/11/14).
139. Ridker, P.M., Cook, N.R., Lee, I.M., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med. 352:13 (2005), 1293–1304.
140. Ritzel, R.M., Capozzi, L.A., McCullough, L.D., Sex, stroke, and inflammation: the potential for estrogen-mediated immunoprotection in stroke. Horm. Behav. 63:2 (2013), 238–253 (Feb).
141. Roach, R.E., Lijfering, W.M., Rosendaal, F.R., Cannegieter, S.C., le Cessie, S., Sex difference in risk of second but not of first venous thrombosis: paradox explained. Circulation 129:1 (2014), 51–56.
142. Rocca, W.A., Grossardt, B.R., Miller, V.M., Shuster, L.T., Brown, R.D. Jr., Premature menopause or early menopause and risk of ischemic stroke. Menopause 19:3 (2012), 272–277 (Mar).
143. Roger, V.L., Go, A.S., Lloyd-Jones, D.M., et al. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation 125:1 (2012), e2–e220.
144. Rosen, E.D., Chan, J.C., Idusogie, E., et al. Mice lacking factor VII develop normally but suffer fatal perinatal bleeding. Nature 390:6657 (1997), 290–294.
145. Rosove, M.H., Brewer, P.M., Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann. Intern. Med. 117:4 (1992), 303–308.
146. Ross, R., Atherosclerosis — an inflammatory disease. N. Engl. J. Med. 340:2 (1999), 115–126 (1999/01/14).
147. Rost, N.S., Wolf, P.A., Kase, C.S., et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 32:11 (2001), 2575–2579 (Nov).
148. Santimone, I., Di Castelnuovo, A., De Curtis, A., et al. White blood cell count, sex and age are major determinants of heterogeneity of platelet indices in an adult general population: results from the MOLI-SANI project. Haematologica 96:8 (2011), 1180–1188.
149. Savitz, S.I., Schlaug, G., Caplan, L., Selim, M., Arterial occlusive lesions recanalize more frequently in women than in men after intravenous tissue plasminogen activator administration for acute stroke. Stroke 36:7 (2005), 1447–1451 (Jul).
150. Schausberger, C.E., Jacobs, V.R., Bogner, G., Wolfrum-Ristau, P., Fischer, T., Hypertensive disorders of pregnancy — a life-long risk?. Geburtshilfe Frauenheilkd. 73:01 (2013), 47–52 (06.02.2013).
151. Scott, C.A., Bewley, S., Rudd, A., et al. Incidence, risk factors, management, and outcomes of stroke in pregnancy. Obstet. Gynecol. 120:2 Pt 1 (2012), 318–324 (Aug).
152. Seshadri, S., Beiser, A., Kelly-Hayes, M., et al. The lifetime risk of stroke: estimates from the Framingham study. Stroke 37:2 (2006), 345–350.
153. Siegerink, B., Govers-Riemslag, J.W., Rosendaal, F.R., Ten Cate, H., Algra, A., Intrinsic coagulation activation and the risk of arterial thrombosis in young women: results from the Risk of Arterial Thrombosis in relation to Oral contraceptives (RATIO) case–control study. Circulation 122:18 (2010), 1854–1861.
154. Silvestrini, M., Vernieri, F., Pasqualetti, P., et al. Impaired cerebral vasoreactivity and risk of stroke in patients with asymptomatic carotid artery stenosis. JAMA 283:16 (2000), 2122–2127.
155. Simon, J.A., Hsia, J., Cauley, J.A., et al. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen–progestin Replacement Study (HERS). Circulation 103:5 (2001), 638–642.
156. Sims, N.R., Muyderman, H., Mitochondria, oxidative metabolism and cell death in stroke. Biochim. Biophys. Acta 1802:1 (2010), 80–91 (Jan).
157. Smith, G.N., Pudwell, J., Walker, M., Wen, S.W., Ten-year, thirty-year, and lifetime cardiovascular disease risk estimates following a pregnancy complicated by preeclampsia. J. Obstet. Gynaecol. Can. 34:9 (2012), 830–835.
158. Smith-Bouvier, D.L., Divekar, A.A., Sasidhar, M., et al. A role for sex chromosome complement in the female bias in autoimmune disease. J. Exp. Med. 205:5 (2008), 1099–1108.
159. Stegeman, B.H., de Bastos, M., Rosendaal, F.R., et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ, 347, 2013, f5298.
160. Steinhubl, S.R., Berger, P.B., Mann, J.T. III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288:19 (2002), 2411–2420.
161. Stirone, C., Chu, Y., Sunday, L., Duckles, S.P., Krause, D.N., 17β-Estradiol increases endothelial nitric oxide synthase mRNA copy number in cerebral blood vessels: quantification by real-time polymerase chain reaction. Eur. J. Pharmacol. 478:1 (2003), 35–38 (9/30/).
162. Stirone, C., Boroujerdi, A., Duckles, S.P., Krause, D.N., Estrogen receptor activation of phosphoinositide-3 kinase, Akt, and nitric oxide signaling in cerebral blood vessels: rapid and long-term effects. Mol. Pharmacol. 67:1 (2005), 105–113.
163. Stirone, C., Duckles, S.P., Krause, D.N., Procaccio, V., Estrogen increases mitochondrial efficiency and reduces oxidative stress in cerebral blood vessels. Mol. Pharmacol. 68:4 (2005), 959–965 (Oct).
164. Suzuki, S., Brown, C.M., Dela Cruz, C.D., Yang, E., Bridwell, D.A., Wise, P.M., Timing of estrogen therapy after ovariectomy dictates the efficacy of its neuroprotective and antiinflammatory actions. Proc. Natl. Acad. Sci. U. S. A. 104:14 (2007), 6013–6018.
165. Tanne, D., D'Olhaberriague, L., Trivedi, A.M., Salowich-Palm, L., Schultz, L.R., Levine, S.R., Anticardiolipin antibodies and mortality in patients with ischemic stroke: a prospective follow-up study. Neuroepidemiology 21:2 (2002), 93–99 (Mar–Apr).
166. Tantry, U.S., Navarese, E.P., Gurbel, P.A., Does gender have an influence on platelet function and the efficacy of oral antiplatelet therapy?. Interv. Cardiol. Clin. 1:2 (2012), 223–230.
167. Tormene, D., Ferri, V., Carraro, S., Simioni, P., Gender and the risk of venous thromboembolism. Semin. Thromb. Hemost. 37:3 (2011), 193–198 (Apr).
168. Towfighi, A., Saver, J.L., Engelhardt, R., Ovbiagele, B., A midlife stroke surge among women in the United States. Neurology 69:20 (2007), 1898–1904.
169. Turtzo, L.C., Siegel, C., McCullough, L.D., X chromosome dosage and the response to cerebral ischemia. J. Neurosci. 31:37 (2011), 13255–13259.
170. Viscoli, C.M., Brass, L.M., Kernan, W.N., Sarrel, P.M., Suissa, S., Horwitz, R.I., A clinical trial of estrogen-replacement therapy after ischemic stroke. N. Engl. J. Med. 345:17 (2001), 1243–1249 (2001/10/25).
171. Wardlaw, J.M., Sandercock, P.A.G., Berge, E., Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cumulative meta-analysis. Stroke 34:6 (2003), 1437–1442.
172. Wassertheil-Smoller, S., Hendrix, S.L., Limacher, M., et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 289:20 (2003), 2673–2684.
173. Weiner, C.P., Lizasoain, I., Baylis, S.A., Knowles, R.G., Charles, I.G., Moncada, S., Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc. Natl. Acad. Sci. U. S. A. 91:11 (1994), 5212–5216.
174. Yang, L., Kuper, H., Sandin, S., et al. Reproductive history, oral contraceptive use, and the risk of ischemic and hemorrhagic stroke in a cohort study of middle-aged Swedish women. Stroke 40:4 (2009), 1050–1058 (Apr).
175. Yee, D.L., Sun, C.W., Bergeron, A.L., Dong, J.F., Bray, P.F., Aggregometry detects platelet hyperreactivity in healthy individuals. Blood 106:8 (2005), 2723–2729.
176. Yuan, M., Siegel, C., Zeng, Z., Li, J., Liu, F., McCullough, L.D., Sex differences in the response to activation of the poly(ADP-ribose) polymerase pathway after experimental stroke. Exp. Neurol. 217:1 (2009), 210–218 (May).
177. Zhang, W., Iliff, J.J., Campbell, C.J., Wang, R.K., Hurn, P.D., Alkayed, N.J., Role of soluble epoxide hydrolase in the sex-specific vascular response to cerebral ischemia. J. Cereb. Blood Flow Metab. 29:8 (2009), 1475–1481 (Aug).
178. Zivin, J.A., Thrombolytic stroke therapy: past, present, and future. Neurology 53:1 (1999), 14–19.